A randomized, open-label, single-dose, two-cycle crossover study to evaluate the bioequivalence and safety of lenvatinib and Lenvima® in Chinese healthy subjects.
Sign Up to like & getrecommendations! Published in 2022 at "Expert opinion on investigational drugs"
DOI: 10.1080/13543784.2022.2067528
Abstract: BACKGROUND Lenvatinib is a tyrosine kinase receptor inhibitor that inhibits vascular and endothelial growth factor receptor kinase activity. This study evaluated the bioequivalence and safety of lenvatinib developed by Chia Tai Tianqing Pharmaceutical Co., Ltd.… read more here.
Keywords: cycle; lenvatinib lenvima; study; bioequivalence safety ... See more keywords